Immunovant (Nasdaq:IMVT) - Prezzo delle azioni, notizie e analisi

IMVT Panoramica delle azioni

Immunovant, Inc. è una società biofarmaceutica in fase clinica che sviluppa anticorpi monoclonali per il trattamento di malattie autoimmuni. Maggiori dettagli

IMVT analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 75.52% all'anno

Gli analisti concordano sul fatto che il prezzo delle azioni salirà di 70.3%

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Importanti vendite da parte di insider negli ultimi 3 mesi

Immunovant, Inc. Concorrenti

CRISPR Therapeutics

NasdaqGM:CRSP

US$4.2b

Turning Point Therapeutics

NasdaqGS:TPTX

US$3.8b

RayzeBio

NasdaqGM:RYZB

US$3.7b

Rhythm Pharmaceuticals

NasdaqGM:RYTM

US$3.8b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Immunovant
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$28.73
Massimo di 52 settimane	US$45.58
Minimo di 52 settimane	US$24.61
Beta	0.71
1Variazione di 1 mese	-4.07%
Variazione a 3 mesi	-7.26%
Variazione di 1 anno	-24.87%
3Variazione a 3 anni	281.54%
Variazione a 5 anni	182.78%
Variazione dall'IPO	188.74%

Notizie e aggiornamenti recenti

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Oct 16

Immunovant: Switching Lead Candidates Increases Risk

Oct 14

Recent updates

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Jan 12

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Sep 28

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Jun 14

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Mar 08

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Nov 06

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Oct 17

Immunovant stock down on raising $75M though equity capital

Oct 04

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Aug 06

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Apr 06

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Jun 20

Immunovant EPS beats by $0.04

Jun 01

argenx rise even as Immunovant pauses the trial for anti-FcRn therapy

Feb 03

Immunovant slips 7% on voluntary hold of IMVT-1401 dosing

Feb 02

Immunovant: IMVT-1401's Indication Expansion, $444M In Cash And New Management

Jan 14

Have Insiders Been Buying Immunovant, Inc. (NASDAQ:IMVT) Shares?

Dec 30

Immunovant (IMVT) Investor Presentation - Slideshow

Nov 16

Rendimenti per gli azionisti

	IMVT	US Biotechs	US Mercato
7D	9.8%	4.3%	1.6%
1Y	-24.9%	18.8%	32.3%

Ritorno vs Industria: IMVT ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 18.8 % nell'ultimo anno.

Rendimento vs Mercato: IMVT ha avuto una performance inferiore al mercato US che ha registrato un rendimento 32.3 % nell'ultimo anno.

Volatilità dei prezzi

Is IMVT's price volatile compared to industry and market?
IMVT volatility
IMVT Average Weekly Movement	6.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: IMVT non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 6% ) di IMVT è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	207	Pete Salzmann	immunovant.com

Immunovant, Inc. è una società biofarmaceutica in fase clinica che sviluppa anticorpi monoclonali per il trattamento di malattie autoimmuni. L'azienda sviluppa batoclimab, un nuovo anticorpo monoclonale completamente umano che ha come bersaglio il recettore cristallizzabile del frammento neonatale per il trattamento della miastenia gravis, della malattia oculare della tiroide, della polineuropatia demielinizzante infiammatoria cronica, delle malattie di Graves e dell'anemia emolitica autoimmune calda. Immunovant, Inc. ha sede a New York, New York.

Immunovant, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Immunovant con la sua capitalizzazione di mercato?
IMVT statistiche fondamentali
Capitalizzazione di mercato	US$3.99b
Guadagni(TTM)	-US$323.01m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-13.1x

Rapporto P/E

IMVT è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
IMVT Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$0
Profitto lordo	US$0
Altre spese	US$323.01m
Guadagni	-US$323.01m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-2.20
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato IMVT nel lungo periodo?

Vedi performance storica e confronto

IMVT Panoramica delle azioni

Premi

Analisi del rischio

Immunovant, Inc. Concorrenti

NasdaqGM:CRSP

US$4.2b

NasdaqGS:TPTX

US$3.8b

NasdaqGM:RYZB

US$3.7b

NasdaqGM:RYTM

US$3.8b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

CEO & Director recently sold US$425k worth of stock

Immunovant, Inc. Appoints Melanie Gloria as Chief Operating Officer, Effective November 18, 2024

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Immunovant: Switching Lead Candidates Increases Risk

Immunovant, Inc. Provides Update on Graves' Disease Development Program

CEO & Director recently sold US$480k worth of stock

Recent updates

CEO & Director recently sold US$425k worth of stock

Immunovant, Inc. Appoints Melanie Gloria as Chief Operating Officer, Effective November 18, 2024

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Immunovant: Switching Lead Candidates Increases Risk

Immunovant, Inc. Provides Update on Graves' Disease Development Program

CEO & Director recently sold US$480k worth of stock

Consensus EPS estimates fall by 17%

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 12, 2024

Immunovant: Next Generation Anti-FcRn Candidate Keeps Hopes Alive

CEO & Director recently sold US$479k worth of stock

CEO & Director recently sold US$990k worth of stock

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant: Strategic Edge In The Autoimmune Sector (Rating Upgrade)

CEO & Director recently sold US$486k worth of stock

New major risk - Revenue and earnings growth

Immunovant: An Intriguing And Developing Story

Immunovant, Inc. (NASDAQ:IMVT) Shares Could Be 33% Below Their Intrinsic Value Estimate

Immunovant, Inc. Announces Results from the Initial Cohort of Patients in an Ongoing 24-Week Phase 2 Clinical Trial of Batoclimab in Patients with Graves' Disease Meaningfully Exceeded 50% Response Rates

Independent Director recently sold US$491k worth of stock

Independent Director notifies of intention to sell stock

Immunovant, Inc. Announces Initial Data from 600 Mg MAD Cohort of A Phase 1 Clinical Trial of IMVT-1402 in Healthy Adults

CEO & Director recently sold US$532k worth of stock

Immunovant, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Immunovant, Inc. announced that it expects to receive $169.999992 million in funding from Roivant Sciences Ltd.

We're Hopeful That Immunovant (NASDAQ:IMVT) Will Use Its Cash Wisely

Immunovant, Inc. Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results

Price target increased by 17% to US$34.42

CEO & Director recently sold US$1.3m worth of stock

Chief Financial Officer recently sold US$292k worth of stock

CEO & Director recently sold US$2.2m worth of stock

CEO & Director recently sold US$2.2m worth of stock

New minor risk - Insider selling

Immunovant, Inc., Annual General Meeting, Aug 21, 2023

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell Small Cap Comp Value Index

Price target increased by 14% to US$28.23

Here's Why We're Not Too Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Situation

Chief Financial Officer recently sold US$52k worth of stock

Immunovant (NASDAQ:IMVT) Is In A Good Position To Deliver On Growth Plans

Price target increased by 11% to US$20.25

Insider recently sold US$188k worth of stock

Chief Development & Technology Officer recently sold US$1.0m worth of stock

Price target increased to US$13.00

Less than half of directors are independent

Price target increased to US$11.00

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant: Capitalizing On Fast Growing FcRn Space With Novel Asset

Chief Financial Officer recently sold US$118k worth of stock

Immunovant stock down on raising $75M though equity capital

Executive Chairperson of the Board recently bought US$116k worth of stock

Immunovant, Inc. Announces IMVT-1402

Immunovant Announces Two New Development Programs for Batoclimab

We're Not Very Worried About Immunovant's (NASDAQ:IMVT) Cash Burn Rate

Immunovant, Inc., Annual General Meeting, Aug 17, 2022

Immunovant, Inc.(NasdaqGS:IMVT) dropped from Russell 2000 Growth Index

Immunovant, Inc. Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease

Immunovant, Inc. to Report Q4, 2022 Results on Jun 08, 2022